187 related articles for article (PubMed ID: 3143016)
1. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study.
Heney NM; Koontz WW; Barton B; Soloway M; Trump DL; Hazra T; Weinstein RS
J Urol; 1988 Dec; 140(6):1390-3. PubMed ID: 3143016
[TBL] [Abstract][Full Text] [Related]
2. First-line chemotherapy of superficial bladder cancer: mitomycin vs thiotepa.
Heney NM
Urology; 1985 Oct; 26(4 Suppl):27-9. PubMed ID: 3931325
[TBL] [Abstract][Full Text] [Related]
3. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
Zincke H; Benson RC; Hilton JF; Taylor WF
J Urol; 1985 Dec; 134(6):1110-4. PubMed ID: 3932685
[TBL] [Abstract][Full Text] [Related]
4. A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers.
Flanigan RC; Ellison MF; Butler KM; Gomella LG; McRoberts JW
J Urol; 1986 Jul; 136(1):35-7. PubMed ID: 3086575
[TBL] [Abstract][Full Text] [Related]
5. Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa.
Mobley WC; Loening SA; Narayana AS; Culp DA
Urology; 1986 Apr; 27(4):335-9. PubMed ID: 3083555
[TBL] [Abstract][Full Text] [Related]
6. Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group.
Koontz WW; Heney NM; Soloway MS; Kluskens L; Hazra TA; Trump DL; Barton B
Urology; 1985 Oct; 26(4 Suppl):30-1. PubMed ID: 3931326
[TBL] [Abstract][Full Text] [Related]
7. Combined thiotepa and mitomycin C instillation therapy for low-grade superficial bladder tumor.
Hu KN; Kim A; Khan AS; Soroff H; Gonder M
Cancer; 1985 Apr; 55(8):1654-8. PubMed ID: 3156664
[TBL] [Abstract][Full Text] [Related]
8. Subsequent tumor analysis of 36 patients who have received intravesical mitomycin C for superficial bladder cancer.
Soloway MS; Ford KS
J Urol; 1983 Jul; 130(1):74-8. PubMed ID: 6408268
[TBL] [Abstract][Full Text] [Related]
9. Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C.
Soloway MS; Perry A
J Urol; 1987 May; 137(5):871-3. PubMed ID: 3106653
[TBL] [Abstract][Full Text] [Related]
10. Transitional cell carcinoma of the prostate following intravesical therapy for transitional cell carcinoma of the bladder.
Hardeman SW; Perry A; Soloway MS
J Urol; 1988 Aug; 140(2):289-92. PubMed ID: 3135420
[TBL] [Abstract][Full Text] [Related]
11. Intravesical mitomycin C therapy for superficial bladder cancer. Report of a multicentre phase II study.
MacFarlane JR; Tolley DA
Br J Urol; 1985 Feb; 57(1):37-9. PubMed ID: 3918605
[TBL] [Abstract][Full Text] [Related]
12. Intravesical therapy of low stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients.
Prout GR; Griffin PP; Nocks BN; DeFuria MD; Daly JJ
J Urol; 1982 Jun; 127(6):1096-8. PubMed ID: 6806488
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer.
Harrison GS; Green DF; Newling DW; Richards B; Robinson MR; Smith PH
Br J Urol; 1983 Dec; 55(6):676-9. PubMed ID: 6418263
[TBL] [Abstract][Full Text] [Related]
14. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
[TBL] [Abstract][Full Text] [Related]
15. Severe bladder contracture in patient receiving intravesical mitomycin C for superficial bladder cancer.
Baker WC; Russo MA; deVere White RW
Urology; 1987 Oct; 30(4):357-8. PubMed ID: 3116739
[TBL] [Abstract][Full Text] [Related]
16. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
Soloway MS; Jordan AM; Murphy WM
Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder.
Pavlotsky A; Eidelman A; Barak F; Alon H; Horn Y
J Surg Oncol; 1989 May; 41(1):9-11. PubMed ID: 2497274
[TBL] [Abstract][Full Text] [Related]
18. Intravesical mitomycin C for the treatment of recurrent superficial bladder tumours.
Hetherington JW; Newling DW; Robinson MR; Smith PH; Adib RS; Whelan P
Br J Urol; 1987 Mar; 59(3):239-41. PubMed ID: 3105631
[TBL] [Abstract][Full Text] [Related]
19. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer.
Br J Urol; 1985 Dec; 57(6):680-5. PubMed ID: 2867800
[TBL] [Abstract][Full Text] [Related]
20. Intravesical chemotherapy for superficial carcinoma of the bladder.
Foo KT; Tan EC; Tung KH; Tock EP
Singapore Med J; 1991 Dec; 32(6):420-2. PubMed ID: 1788600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
